121 related articles for article (PubMed ID: 35588226)
1. Hematologic Toxicity Comparison of Intensity Modulated Proton Therapy and Intensity Modulated Radiation Therapy in Anal Cancer Patients.
Nelson B; Tadesse DG; Sudhoff M; Wang K; Meier T; Mascia A; Kharofa J
Am J Clin Oncol; 2022 Jun; 45(6):264-267. PubMed ID: 35588226
[TBL] [Abstract][Full Text] [Related]
2. Feasibility Trial of Intensity Modulated Proton Therapy to Reduce Toxicity in Anal Cancer Patients.
Nelson B; Meier T; Zhang Y; Wang K; Mascia AE; Paquette I; Thompson E; Rafferty J; Snyder J; Olowokure O; Sohal D; Kharofa J
Am J Clin Oncol; 2023 Jul; 46(7):293-299. PubMed ID: 37088904
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging.
Qin X; Gong G; Wang L; Su Y; Yin Y
Radiat Oncol; 2022 Dec; 17(1):207. PubMed ID: 36517839
[TBL] [Abstract][Full Text] [Related]
4. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Yu NY; DeWees TA; Voss MM; Breen WG; Chiang JS; Ding JX; Daniels TB; Owen D; Olivier KR; Garces YI; Park SS; Sarkaria JN; Yang P; Savvides PS; Ernani V; Liu W; Schild SE; Merrell KW; Sio TT
Clin Lung Cancer; 2022 Dec; 23(8):e526-e535. PubMed ID: 36104272
[TBL] [Abstract][Full Text] [Related]
5. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
7. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric Comparison of Intensity-Modulated Proton Therapy and Volumetric-Modulated Arc Therapy in Anal Cancer Patients and the Ability to Spare Bone Marrow.
Meier T; Mascia A; Wolf E; Kharofa J
Int J Part Ther; 2017; 4(2):11-17. PubMed ID: 31773004
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
10. Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.
Robinson M; Sabbagh A; Muirhead R; Durrant L; Van den Heuvel F; Hawkins M
Radiother Oncol; 2015 Nov; 117(2):246-51. PubMed ID: 26409831
[TBL] [Abstract][Full Text] [Related]
11. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
Moreno AC; Frank SJ; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Williamson TD; Holliday EB; Phan J; Blanchard P
Oral Oncol; 2019 Jan; 88():66-74. PubMed ID: 30616799
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
Zhang W; Zhang X; Yang P; Blanchard P; Garden AS; Gunn B; Fuller CD; Chambers M; Hutcheson KA; Ye R; Lai SY; Radwan MAS; Zhu XR; Frank SJ
Radiother Oncol; 2017 Jun; 123(3):401-405. PubMed ID: 28549794
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison.
Nguyen ML; Cantrell JN; Ahmad S; Henson C
Med Dosim; 2021 Autumn; 46(3):259-263. PubMed ID: 33648823
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
Gjyshi O; Xu T; Elhammali A; Boyce-Fappiano D; Chun SG; Gandhi S; Lee P; Chen AB; Lin SH; Chang JY; Tsao A; Gay CM; Zhu XR; Zhang X; Heymach JV; Fossella FV; Lu C; Nguyen QN; Liao Z
J Thorac Oncol; 2021 Feb; 16(2):269-277. PubMed ID: 33198942
[TBL] [Abstract][Full Text] [Related]
16. Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Cortiula F; Hendriks LEL; Wijsman R; Houben R; Steens M; Debakker S; Canters R; Trovò M; Sijtsema NM; Niezink AGH; Unipan M; Urban S; Michelotti A; Dursun S; Bootsma G; Hattu D; Nuyttens JJ; Moretti E; Taasti VT; De Ruysscher D
Radiother Oncol; 2024 Jan; 190():110019. PubMed ID: 38000689
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer.
Zhang Y; Fan B; Sun T; Xu J; Yin Y; Chen Z; Zhu J; Yu J; Hu M
J Cancer Res Ther; 2022 Sep; 18(5):1261-1267. PubMed ID: 36204871
[TBL] [Abstract][Full Text] [Related]
18. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma.
Hung HM; Chan OCM; Mak CH; Hung WM; Ng WT; Lee MCH
Med Dosim; 2022 Spring; 47(1):14-19. PubMed ID: 34470708
[TBL] [Abstract][Full Text] [Related]
20. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
